Natus Medical Soars After Announcing Acquisition By ArchiMed
Natus Medical (NTUS) investors see huge gains on Monday from news that the Company is being acquired by investment firm ArchiMed for approximately $1.2 billion.
Natus is housed in the MedDiagnostics PRISM Index as the Company is a maker of medical devices for diagnosing and treating brain and nervous system disorders.
ArchiMed will pay Natus shareholders $33.50 per share, which is a 29% premium based on the stock’s closing price on April 14.
The chairman of Natus, Joshua Levine, stated that “The sale of Natus to ArchiMed will provide our shareholders with immediate and substantial cash value, as well as a compelling premium, and the Board has unanimously agreed that this transaction is in the best interests of our shareholders.”